MiNK Therapeutics, Inc.(INKT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INKT MiNK Therapeutics, Inc.

已收盘 09-09 16:00:00 EDT

11.90

+0.45

+3.93%

盘后11.90

+0.000.00%

19:30 EDT

最高12.15	最低11.54	成交量1.70万
今开11.54	昨收11.45	日振幅5.41%
总市值6,073万	流通市值2,467万	总股本510.30万
成交额20.20万	换手率0.82%	流通股本207.33万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INKT","market":"US","secType":"STK","nameCN":"MiNK Therapeutics, Inc.","latestPrice":11.9,"timestamp":1788984000000,"preClose":11.45,"halted":0,"volume":16968,"hourTrading":{"tag":"盘后","latestPrice":11.9,"preClose":11.9,"latestTime":"19:30 EDT","volume":133,"amount":1595.77,"timestamp":1788996607108,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03930131004366822,"floatShares":2073300,"shares":5103000,"eps":-2.39704,"marketStatus":"已收盘","change":0.45,"latestTime":"09-09 16:00:00 EDT","open":11.535,"high":12.1549,"low":11.535,"amount":201979.419432,"amplitude":0.05414,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.39704,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789027200000},"marketStatusCode":5,"adr":0,"listingDate":1634270400000,"exchange":"NASDAQ","adjPreClose":11.45,"preHourTrading":{"tag":"盘前","latestPrice":11.31,"preClose":11.45,"latestTime":"09:29 EDT","volume":1,"amount":11.31,"timestamp":1788960597066,"change":-0.14,"changeRate":-0.012227,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":11.9,"preClose":11.9,"latestTime":"19:30 EDT","volume":133,"amount":1595.77,"timestamp":1788996607108,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.772821},"requestUrl":"/m/hq/s/INKT/wiki","defaultTab":"wiki","newsList":[{"id":"1134232765","title":"MiNK Therapeutics公布2026年第二季度财务业绩及Agent-797治疗急性肺损伤II期随机试验观察结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1134232765","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134232765?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:32","pubTimestamp":1786620725,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics, Inc. 发布了其2026年第二季度的财务报告，并同步披露了关于Agent-797在急性肺损伤治疗中的随机II期临床试验观察数据。这份公告整合了财务表现与关键研发进展——后者聚焦于这款候选药物对特定急重症患者群体的潜在疗效。财务数据与试验观察结果的同步释出，为市场提供了审视该公司运营现状及管线前景的双重窗口。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142218910","title":"MiNK Therapeutics 临床试验持续推进：利沃夫入组进行中，美国中心即将启动；更多数据预计2027年初公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1142218910","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142218910?lang=zh_cn&edition=full","pubTime":"2026-08-07 00:04","pubTimestamp":1786032251,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics 正在稳步推进其临床试验进程。目前，在乌克兰利沃夫的受试者入组工作仍在持续进行中。与此同时，美国境内的多个试验中心也即将开放，标志着该研究进入了一个新的关键阶段。公司方面透露，更多的临床数据预计将在2027年年初公布，届时将为市场带来更清晰的疗效评估依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135857524","title":"MiNK Therapeutics宣布首例患者入组Agent-797治疗急性肺损伤与危重疾病的随机二期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1135857524","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135857524?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:06","pubTimestamp":1779973587,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics宣布，其候选药物Agent-797在针对急性肺损伤及危重疾病的随机二期临床试验中，已完成首例患者给药。这项试验旨在评估该药物的安全性与有效性，标志着其在相关治疗领域临床开发的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179318143","title":"MiNK Therapeutics与利沃夫第一地区医疗联盟启动AGENT-797治疗急性肺损伤与危重症的随机二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1179318143","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179318143?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:31","pubTimestamp":1778758295,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics与利沃夫第一地区医疗联盟已正式启动一项随机二期临床试验，旨在评估其候选药物AGENT-797在治疗急性肺损伤及危重症患者中的疗效与安全性。这项研究的启动标志着该疗法在应对严重呼吸系统疾病方面迈入了新的临床验证阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115369642","title":"MiNK Therapeutics将公布2026年第一季度财报并重点展示iNKT细胞治疗平台进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1115369642","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115369642?lang=zh_cn&edition=full","pubTime":"2026-05-09 04:31","pubTimestamp":1778272298,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics, Inc. (INKT)计划发布其2026年第一季度的财务业绩报告。与此同时，公司还将重点介绍其专有平台在多个iNKT细胞治疗项目上取得的研发进展。此次信息发布旨在让投资者全面了解公司的财务状况以及其核心治疗技术管线的推进情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180186682","title":"MiNK Therapeutics公布PD-1耐药性胃食管癌免疫重编程与长期生存II期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1180186682","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180186682?lang=zh_cn&edition=full","pubTime":"2026-04-18 03:01","pubTimestamp":1776452472,"startTime":"0","endTime":"0","summary":"生物技术公司MiNK Therapeutics, Inc.近日披露了其针对PD-1抑制剂难治性胃食管癌的II期临床试验数据。研究结果显示，该疗法在诱导免疫系统重编程方面展现出潜力，并观察到患者获得持久生存获益的积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196114672","title":"MiNK Therapeutics公司正就潜在联合试验及战略少数股权投资进行洽谈 - 美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1196114672","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196114672?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:42","pubTimestamp":1774622541,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会的文件显示，生物制药公司MiNK Therapeutics, Inc.目前正处于积极商讨阶段，涉及两项关键战略举措。公司正在探索开展潜在联合临床试验的可能性，旨在评估其研发管线与其他疗法的协同效应。与此同时，MiNK Therapeutics也在就引入战略少数股权投资进行深入讨论。上述动向表明，MiNK Therapeutics正致力于通过外部合作与资本运作，推动其技术平台和候选药物的进一步发展，以最大化其长期价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129958099","title":"MiNK Therapeutics任命Melissa Orilall为首席财务官，自2026年3月13日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1129958099","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129958099?lang=zh_cn&edition=full","pubTime":"2026-03-20 05:25","pubTimestamp":1773955505,"startTime":"0","endTime":"0","summary":"生物制药公司MiNK Therapeutics, Inc.宣布了一项重要人事任命。公司已正式任命Melissa Orilall女士担任首席财务官一职，此项任命将于2026年3月13日正式生效。\n此次高管变动已通过美国证券交易委员会的相关文件进行披露，标志着公司财务战略管理即将进入新的阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194124444","title":"MiNK Therapeutics将公布2025年第四季度及全年财报 重点展示iNKT细胞疗法平台扩展成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1194124444","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194124444?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:31","pubTimestamp":1773747074,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics, Inc.宣布将于近期披露2025年第四季度及全年财务业绩报告。此次公告将同步展示公司在iNKT细胞治疗项目矩阵中的平台化拓展突破，凸显其技术平台在多条研发管线中的协同应用价值。财务数据与治疗平台进展的双重披露，将全面呈现企业从技术探索到商业化布局的战略脉络。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103552874","title":"MiNK Therapeutics股价盘前飙升70%，此前C-Further获110万美元资助推进儿科癌症细胞疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1103552874","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103552874?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:07","pubTimestamp":1773137227,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics公司股价在盘前交易中大幅上涨70%，此前该公司宣布其合作伙伴C-Further获得高达110万美元的资金支持，用于推进儿科癌症细胞疗法的研发。\n这笔资金将加速C-Further在儿科癌症细胞治疗领域的研究进程，为MiNK Therapeutics的技术发展提供了有力支持。市场对此消息反应积极，显示出投资者对公司未来前景的看好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118579355","title":"MiNK Therapeutics将获110万美元资助 用于推进PRAME-TCR-iNKT资产IND支持研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1118579355","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118579355?lang=zh_cn&edition=full","pubTime":"2026-03-10 17:32","pubTimestamp":1773135159,"startTime":"0","endTime":"0","summary":"生物技术公司MiNK Therapeutics, Inc.宣布，公司将获得110万美元资金支持，专项用于其PRAME-TCR-iNKT候选药物的IND（新药临床研究申请）启发性研发工作。该笔资金将加速推进这一创新肿瘤免疫疗法的临床前开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144332941","title":"MiNK Therapeutics携手C-Further推进PRAME靶向iNKT细胞疗法治疗儿科癌症","url":"https://stock-news.laohu8.com/highlight/detail?id=1144332941","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144332941?lang=zh_cn&edition=full","pubTime":"2026-03-10 17:32","pubTimestamp":1773135142,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics宣布与C-Further达成合作，共同推进针对儿科癌症的PRAME靶向iNKT细胞疗法的研发进程。这一合作将结合双方在免疫细胞治疗领域的专业优势，加速创新疗法的临床转化，为儿童癌症患者提供新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518308222","title":"Mink Therapeutics, Inc.盘中异动 早盘急速跳水8.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518308222","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518308222?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:44","pubTimestamp":1741614241,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时44分，Mink Therapeutics, Inc.股票出现异动，股价快速跳水8.05%。Mink Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Trevi Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2390.07%、561.77%、84.34%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Mink Therapeutics, Inc.公司简介：.MiNK Therapeutics Inc是一家临床阶段的生物制药公司，专注开发同种异体不变的自然杀伤T细胞疗法，以治疗癌症和其他危及生命的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214401abf30117&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214401abf30117&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INKT","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517947192","title":"Mink Therapeutics, Inc.盘中异动 股价大涨6.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517947192","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517947192?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:42","pubTimestamp":1741196552,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时42分，Mink Therapeutics, Inc.股票出现异动，股价大幅拉升6.30%。Mink Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.25%。Mink Therapeutics, Inc.公司简介：.MiNK Therapeutics Inc是一家临床阶段的生物制药公司，专注开发同种异体不变的自然杀伤T细胞疗法，以治疗癌症和其他危及生命的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306014232963b06ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306014232963b06ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INKT","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677322","title":"Mink Therapeutics, Inc.盘中异动 快速下挫9.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677322","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677322?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:30","pubTimestamp":1741098649,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时30分，Mink Therapeutics, Inc.股票出现波动，股价急速跳水9.47%。Mink Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Mink Therapeutics, Inc.公司简介：.MiNK Therapeutics Inc是一家临床阶段的生物制药公司，专注开发同种异体不变的自然杀伤T细胞疗法，以治疗癌症和其他危及生命的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223050989bab88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223050989bab88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513629652","title":"Mink Therapeutics, Inc.盘中异动 早盘快速拉升5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513629652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513629652?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:34","pubTimestamp":1740148490,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时34分，Mink Therapeutics, Inc.股票出现波动，股价急速上涨5.30%。Mink Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。Mink Therapeutics, Inc.公司简介：.MiNK Therapeutics Inc是一家临床阶段的生物制药公司，专注开发同种异体不变的自然杀伤T细胞疗法，以治疗癌症和其他危及生命的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223450abd7b04e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223450abd7b04e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INKT","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510380389","title":"Mink Therapeutics, Inc.盘中异动 早盘大幅上涨6.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510380389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510380389?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:32","pubTimestamp":1739284345,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时32分，Mink Therapeutics, Inc.股票出现异动，股价快速拉升6.43%。Mink Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.10%。Mink Therapeutics, Inc.公司简介：.MiNK Therapeutics Inc是一家临床阶段的生物制药公司，专注开发同种异体不变的自然杀伤T细胞疗法，以治疗癌症和其他危及生命的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223227961f47be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223227961f47be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509277498","title":"Mink Therapeutics, Inc.盘中异动 快速拉升5.67%报11.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509277498","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509277498?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:44","pubTimestamp":1738853044,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时44分，Mink Therapeutics, Inc.股票出现异动，股价快速拉升5.67%。截至发稿，该股报11.47美元/股，成交量9870股，换手率0.25%，振幅8.02%。Mink Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Mink Therapeutics, Inc.公司简介：.MiNK Therapeutics Inc是一家临床阶段的生物制药公司，专注开发同种异体不变的自然杀伤T细胞疗法，以治疗癌症和其他危及生命的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206224404a23bd15a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206224404a23bd15a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INKT","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508457999","title":"Mink Therapeutics, Inc.盘中异动 早盘大幅下跌6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508457999","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508457999?lang=zh_cn&edition=full","pubTime":"2025-02-04 22:38","pubTimestamp":1738679939,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日22时38分，Mink Therapeutics, Inc.股票出现异动，股价快速跳水6.87%。Mink Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。Mink Therapeutics, Inc.公司简介：.MiNK Therapeutics Inc是一家临床阶段的生物制药公司，专注开发同种异体不变的自然杀伤T细胞疗法，以治疗癌症和其他危及生命的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223859987a4b93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223859987a4b93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508149126","title":"Mink Therapeutics, Inc.盘中异动 早盘快速跳水5.24%报8.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508149126","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508149126?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:32","pubTimestamp":1738593129,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时32分，Mink Therapeutics, Inc.股票出现异动，股价快速跳水5.24%。Mink Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.51%。Mink Therapeutics, Inc.公司简介：.MiNK Therapeutics Inc是一家临床阶段的生物制药公司，专注开发同种异体不变的自然杀伤T细胞疗法，以治疗癌症和其他危及生命的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223209abc106da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223209abc106da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INKT","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.minktherapeutics.com;investor.minktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0457},{"period":"1month","weight":0.0457},{"period":"3month","weight":-0.0607},{"period":"6month","weight":0.1138},{"period":"1year","weight":-0.2767},{"period":"ytd","weight":0.0269}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":-0.0094},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.15},{"period":"1year","weight":0.1805},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MiNK Therapeutics, Inc.于2017年7月在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，率先发现、开发和商业化同种异体、现成的iNKT细胞疗法，以治疗癌症和其他免疫介导的疾病。该公司正在利用其平台和制造能力开发一条全资或独家许可的天然和工程iNKT细胞管道，并预计在2021年和2022年进行多项临床和临床前读数。公司的战略是推进可访问、可扩展且有效的细胞治疗平台，利用iNKT细胞的先天和持久的生物学优势，优化可扩展性和快速临床开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.041395},{"month":2,"riseRate":0.2,"avgChangeRate":-0.047548},{"month":3,"riseRate":0,"avgChangeRate":-0.079206},{"month":4,"riseRate":0.4,"avgChangeRate":0.010238},{"month":5,"riseRate":0,"avgChangeRate":-0.080325},{"month":6,"riseRate":0.4,"avgChangeRate":0.018096},{"month":7,"riseRate":0.2,"avgChangeRate":0.152031},{"month":8,"riseRate":0.4,"avgChangeRate":0.128048},{"month":9,"riseRate":0.2,"avgChangeRate":-0.099513},{"month":10,"riseRate":0.5,"avgChangeRate":-0.021174},{"month":11,"riseRate":0.6,"avgChangeRate":-0.066406},{"month":12,"riseRate":0.4,"avgChangeRate":-0.119867}],"exchange":"NASDAQ","name":"MiNK Therapeutics, Inc.","nameEN":"MiNK Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MiNK Therapeutics, Inc.(INKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MiNK Therapeutics, Inc.(INKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MiNK Therapeutics, Inc.,INKT,MiNK Therapeutics, Inc.股票,MiNK Therapeutics, Inc.股票老虎,MiNK Therapeutics, Inc.股票老虎国际,MiNK Therapeutics, Inc.行情,MiNK Therapeutics, Inc.股票行情,MiNK Therapeutics, Inc.股价,MiNK Therapeutics, Inc.股市,MiNK Therapeutics, Inc.股票价格,MiNK Therapeutics, Inc.股票交易,MiNK Therapeutics, Inc.股票购买,MiNK Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MiNK Therapeutics, Inc.(INKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MiNK Therapeutics, Inc.(INKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}